Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410806 | 0.79 | MAPT (0.51) | HPGDMEN1KMT2AAPOBEC3GPPARG | |
| SCHEMBL422287 | 0.73 | MARS1 (0.39) | MEN1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL414623 | 0.70 | ALDH1A1 (0.34) | HPGDMEN1KMT2AAPOBEC3GPPARG | |
| SCHEMBL10469186 | 0.70 | L3MBTL1 (0.68) | HPGDAPOBEC3GALDH1A1KDM4ETSHR | |
| SCHEMBL10217277 | 0.69 | MAPT (0.39) | HPGDMEN1KMT2AAPOBEC3GPPARG | |
| SCHEMBL6389138 | 0.68 | MAPT (0.70) | HPGDMEN1KMT2AAPOBEC3GALDH1A1 | |
| SCHEMBL8632250 | 0.68 | ALDH1A1 (0.49) | HPGDMEN1KMT2AAPOBEC3GPPARG | |
| SCHEMBL3584589 | 0.66 | ADORA2B (0.42) | HPGDMEN1KMT2AAPOBEC3GALDH1A1 | |
| SCHEMBL5391867 | 0.65 | CYP3A4 (0.45) | HPGDMEN1KMT2AAPOBEC3GALDH1A1 | |
| SCHEMBL8047315 | 0.65 | TDP1 (0.51) | HPGDMEN1KMT2AAPOBEC3GALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408751-B1 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER IP GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| EP-2408751-B1 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER IP GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| US-8796324-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-8796324-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-8796324-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-8202895-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202895-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202895-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-19 | — | — | US | disclosed |
| EP-2408751-A1 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | Bayer Pharma Aktiengesellschaft (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| WO-2010105770-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010105770-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | HPGD 782/4885MEN1 3285/4885KMT2A 2731/4885 |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | HPGD 782/4885MEN1 3285/4885KMT2A 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.